Literature DB >> 10809192

Increased cerebral iron uptake in Wilson's disease: a 52Fe-citrate PET study.

M Bruehlmeier1, K L Leenders, P Vontobel, C Calonder, A Antonini, A Weindl.   

Abstract

UNLABELLED: Toxicity of abundant copper is the main cause of brain and liver tissue damage in patients with Wilson's disease (WD). However, there is also evidence of a disturbed iron metabolism in this genetically determined disorder. This PET study was undertaken to assess cerebral iron metabolism in WD patients.
METHODS: We used 52Fe-citrate, which converts to 52Fe-transferrin in blood plasma, to study basic pharmacokinetic features of the cerebral iron transport in 6 WD patients and in 16 healthy volunteers (control subjects). A 2-tissue-compartment model and multiple time graphic plotting were used to calculate 52Fe-transferrin distribution volumes and transport rates.
RESULTS: Net iron uptake (Ki) from plasma into brain tissue was significantly (P < 0.001) higher in WD patients (Ki [mean +/- SEM] = 15.1E-05 +/- 7.13E-05 [1/min]) than in healthy volunteers (Ki = 2.66E-05 +/- 0.351E-05 [1/min]). There was no difference of tracer iron distribution in the cerebral plasma volume between patients and healthy volunteers. Iron uptake values resulting from 2 methods to model PET data of patients and healthy volunteers were highly correlated (P < 0.001).
CONCLUSION: An abnormally increased cerebral 52Fe-transferrin uptake was found in WD patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10809192

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  17 in total

1.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

2.  Lenticular nucleus hyperechogenicity in Wilson's disease reflects local copper, but not iron accumulation.

Authors:  Uwe Walter; Marta Skowrońska; Tomasz Litwin; Grażyna Maria Szpak; Katarzyna Jabłonka-Salach; David Skoloudík; Ewa Bulska; Anna Członkowska
Journal:  J Neural Transm (Vienna)       Date:  2014-03-11       Impact factor: 3.575

3.  Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Authors:  Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis
Journal:  Inorg Chem       Date:  2013-12-06       Impact factor: 5.165

4.  Wilson's disease patient with iron metabolism discharge barriers: A case report.

Authors:  Guoen Cai; Xinming Huang; Qinyong Ye; Wenting Xiong; Qing Duan
Journal:  Exp Ther Med       Date:  2016-11-24       Impact factor: 2.447

Review 5.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 6.  Contribution of metals to brain MR signal intensity: review articles.

Authors:  Tomonori Kanda; Yudai Nakai; Shuri Aoki; Hiroshi Oba; Keiko Toyoda; Kazuhiro Kitajima; Shigeru Furui
Journal:  Jpn J Radiol       Date:  2016-03-01       Impact factor: 2.374

Review 7.  Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography.

Authors:  Fang Xie; Fangyu Peng
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 8.  A nuclear chocolate box: the periodic table of nuclear medicine.

Authors:  Philip J Blower
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

9.  The effect of gender on brain MRI pathology in Wilson's disease.

Authors:  T Litwin; G Gromadzka; A Członkowska; M Gołębiowski; R Poniatowska
Journal:  Metab Brain Dis       Date:  2013-01-15       Impact factor: 3.584

10.  Susceptibility-Weighted Imaging Manifestations in the Brain of Wilson's Disease Patients.

Authors:  Jinjing Yang; Xiaohu Li; Renmin Yang; Xuen Yu; Changliang Yu; Yinfeng Qian; Yongqiang Yu
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.